Helex, a therapeutics startup based in Hyderabad which recently declared the successful completion of a $3.5 million seed investment round. One of the major investors, which demonstrated confidence in the vision of Helex in precision medicine, was the seed round led by pi Ventures. Other investors such as Bluehill Capital, SOSV, and a global syndicate of other investors were also present during the round. This capital injection will raise the total capital raised to date by Helex to more than $6 million and place the company on a firmer financial standing as it is poised to enter clinical development.
Fresh capital and expansion
The new funding will be the crucial validation of the strategy that Helex has for managing incurable genetic kidney diseases. The collected $3.5 million will be thoroughly spent in the two major strategic areas, which are of paramount importance to the development of the Helex platform. A large part of the capital is allocated to speed up the optimization of the leading gene-editing candidate in the company. This candidate is particularly tailored to meet the medical needs of a high-prevalence inherited disease, Autosomal Dominant Polycystic Kidney Disease (ADPKD). The speeding up of this program is also meant to shorten the time frame before this potential breakthrough therapy is made available to patients.
The capital will be utilized to significantly scale up the proprietary AI-based therapeutics platform of Helex. This platform is the heart of the company in terms of innovation, as it is concerned with the identification and targeting of genetic kidney diseases. The growth includes increasing the scale and complexity of the AI models, enabling the platform to design and validate new therapeutic candidates in a faster and more accurate way.
Through deep learning and the use of computation, Helex plans to expand the number of programmable medicines continuously, beyond the lead candidate to treat more debilitating kidney diseases. This two-fold focus guarantees the company not only develops its present most promising asset, but also enhances the technology behind it that will bring its future pipeline forward.
Supportive ecosystem and technological foundation
Helex was founded in 2021 by three founders, Poulami Chaudhuri, Rohini Kalvakuntla, and Anirudh Nishtala. The company is established based on the creation of a new, differentiated type of targeted genetic medicines. These treatments are aimed at transforming the underlying approaches to chronic and rare kidney disease treatment by focusing not only on symptom management but also on the underlying genetic causes of the condition. At ASPIRE-BioNEST, University of Hyderabad, Helex is incubating in a favorable ecosystem of deep-tech biology innovation.
The most prominent technological foundation of Helex is its new delivery system and advanced design platform. The firm uses an LNP (Lipid Nanoparticle) delivery system that is safe and efficient in delivering its therapeutic cargo. LNPs are an essential factor, as they facilitate the use of genetic cargo that can be transported to the target cells within the kidney. This is combined with a drug design platform that uses AI and introduces an unprecedented level of precision to the process.
It is a proprietary platform that calculates high volumes of genomics data and bioinformatics with high-throughput sequencing. This information-rich platform enables the site to perform the important task of planning and verifying disease-centered gRNAs (guide RNAs) with deep learning models.
Through deep learning, Helex has an excellent opportunity to greatly increase the therapeutic accuracy of its gene-editing technology and simultaneously strive to reduce off-target events. The long-term aim of this technological convergence is the development of programmable but non-viral therapeutics, which are safer and possibly more scalable than the conventional methods of viral delivery, capable of efficiently altering the relevant genetic pathways in kidney cells.
Global health challenges and aim to develop
The short-term and urgent interest of Helex is Autosomal Dominant Polycystic Kidney Disease (ADPKD). It is a progressive inherited disease that is devastating to the patient with global effects, as it causes many cysts to develop in the kidneys, which leads to kidney failure in most cases.
The disease poses a major health challenge in the world, with more than 12 million individuals being infected. The effects are significantly experienced in India, where ADPKD accounts for about 5% of the total number of Chronic Kidney Disease (CKD).
The company hopes to innovate a solution in this high-need field, a single-dose, non-viral gene-editing therapy. The proposed treatment is not simply aimed at slowing down the deterioration of the kidney condition, but it should be able to stop or at least decelerate the disease process altogether. This would be a paradigm shift in the management of ADPKD, where the focus is not on managing the constant symptoms but on a possible cure in one intervention.
Conclusion
The seed funding of Helex of $3.5 million is a critical step that allows the company to shift its groundbreaking research in gene editing to a practical therapeutic advancement. Through its strategic approach of speeding up its lead ADPKD candidate and diversifying its advanced AI-based delivery system, Helex is establishing itself as a major player in the kidney therapeutics environment. The company has a focus on creating programmable, non-viral genetic medicines, which fulfils the urgency to be precise, safe, and scalable in the treatment of diseases that plague millions of people worldwide. The new financing is a key milestone on the way to achieving the goal of the founders of launching gene-editing-based kidney therapeutics into clinical practice.
Read the full article here
